Gregory Loewen
Pulmonary Disease · Elmira, NYNPI 1306836499
Payments from drug & device makers
Across 158 payments — averaging $39.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Concordia Laboratories Inc.$4K
- GSK$619
- AstraZeneca$501
- Boehringer Ingelheim$320
- Johnson & Johnson$262
- Grifols USA, LLC$194
- plus $727 from 19 others
What the payments were for
- Consulting fees$3,60058%
- Food & beverage$2,60442%
- Education$180%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Concordia Laboratories Inc. | 2 | $3,600 |
| GSK | 55 | $619 |
| AstraZeneca | 27 | $501 |
| Boehringer Ingelheim | 18 | $320 |
| Johnson & Johnson | 2 | $262 |
| Grifols USA, LLC | 11 | $194 |
| Regeneron Healthcare Solutions, Inc. | 5 | $103 |
| Sanofi | 6 | $102 |
| Electromed, Inc. | 5 | $78 |
| Actelion Pharmaceuticals US, Inc. | 3 | $73 |
| Mylan Specialty L.p. | 4 | $59 |
| Sunovion Pharmaceuticals Inc. | 4 | $37 |
| Philips North America LLC | 2 | $33 |
| Nabriva Therapeutics, PLC | 2 | $29 |
| Mallinckrodt Enterprises LLC | 1 | $27 |
| Teva Pharmaceuticals USA, Inc. | 2 | $26 |
| Atricure, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $21 |
| Vapotherm Inc | 1 | $20 |
| Insmed, Inc. | 1 | $20 |
| Astellas Pharma US Inc | 1 | $18 |
| United Therapeutics Corporation | 1 | $18 |
| Gilead | 1 | $15 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
| Mallinckrodt Hospital Products Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,222 in reported general payments places this provider in the 70th percentile of 1,115 pulmonary disease providers in New York.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 140 | $118,423 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $43,392 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $14,246 |
| Spiriva RespimatTiotropium Bromide | 16 | $10,616 |
| SymbicortBudesonide/Formoterol Fumarate | 40 | $8,700 |
| Combivent RespimatIpratropium/Albuterol Sulfate | 14 | $7,594 |
| Incruse ElliptaUmeclidinium Bromide | 12 | $4,454 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 107 | $3,045 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 14 | $2,153 |
| Mometasone Furoate | 12 | $766 |
| Pramipexole DihydrochloridePramipexole Di-Hcl | 17 | $254 |
| Prednisone | 24 | $200 |
| Montelukast Sodium | 34 | $191 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta, Incruse Ellipta | $619 | $137,124176 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $501 | $52,093106 claims |
| Boehringer IngelheimSpiriva Respimat, Combivent Respimat | $320 | $18,21030 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in Elmira
- Linda RogersNew York$7.1M
- Maria PadillaNew York$3.6M
- R WhiteRochester$3.1M
- Juan WisniveskyNew York$3M
- Bushra MinaNew York$2.5M
- Robert KanerNew York$2.3M
- Negin HajizadehGreenport$2M
- Doreen Addrizzo-HarrisNew York$1.9M
- Sherif El BayadiSyracuse$1.9M
- Daniel LachantRochester$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.